Cargando…
No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
INTRODUCTION: No head-to-head trials have compared the efficacy of the oral therapies, fingolimod, dimethyl fumarate and teriflunomide, in multiple sclerosis. Statistical modeling approaches, which control for differences in patient characteristics, can improve indirect comparisons of the efficacy o...
Autores principales: | Nixon, Richard, Bergvall, Niklas, Tomic, Davorka, Sfikas, Nikolaos, Cutter, Gary, Giovannoni, Gavin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245493/ https://www.ncbi.nlm.nih.gov/pubmed/25414048 http://dx.doi.org/10.1007/s12325-014-0167-z |
Ejemplares similares
-
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021) -
Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022) -
“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2017) -
Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023) -
Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)